During atherosclerosis, lipid-rich plaques are formed in large- and medium-sized arteries, which can reduce blood flow to tissues. This situation becomes particularly precarious when a plaque develops ...

In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability ...

IFNs are known to be important mediators in atherosclerosis. Evidence from both in vitro and in vivo studies shows that the IFNs are generally proatherosclerotic. However, their role in ...

The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

Atherosclerosis (AS) is a leading cause of mortality worldwide. AS is a progressive disease and so, early detection and intervention can lead to huge health benefits while also reducing the associated ...